11 results about "Hormone release" patented technology

The present application relates to azapeptide compounds of formula (I) derived from melanocyte-stimulating hormone release-inhibiting factor-1. A method to obtain compounds of formula (I) is also described herein. The compounds of formula (I) have been shown to be suitable for the treatment of dopamine-related disorders of the central nervous system. These compounds showed enhanced potency as positive allosteric modulators of the dopamine D2 receptors in comparison with the melanocyte-stimulating hormone release- inhibiting factor-1 and, in general, do not exhibit meaningful cytotoxicity.

The invention discloses a regulation and control method for enhancing photosynthetic efficiency through hormone signal transduction between grafted rootstocks and scions, and particularly relates to the field of photosynthetic efficiency regulation and control. The regulation and control method comprises the steps that hormone release data of rootstocks, photosynthetic response data of scions and corresponding time labels are obtained, and according to the time difference between hormone change and photosynthetic response, the photosynthetic response data of the scions are obtained; constructing a state sequence with a delay tag; and defining an action set according to the delay characteristics marked in the state sequence. By constructing a state transition structure of delayed response perception and a regulation strategy generation mechanism based on a time recursion feature, an onset time point of a hormone signal and a feedback response track of a scion are captured, and accurate identification and intervention opportunity optimization of a regulation window in a non-dominant coupling chain are realized; therefore, the problems that an existing model cannot effectively model a time evolution structure, strategy execution is distorted, and improvement of photosynthetic efficiency is difficult to stably capture are solved.

An implant that can be implanted non-invasive or minimally-invasively into the sphenoid cavity of a subject for delivery of stimulation to deep brain reward circuit nodes of the brain and / or to drive hormonal release through stimulation of nuclei in the hippocampus or cells in the pituitary or nearby structures such as blood vessels. The implant is alternatively or additionally capable of sensing signals in the deep brain, and for powering deep-brain implants (i.e., devices placed in the brain that are difficult to power from the scalp due to distance).

To provide luteinizing hormone-releasing hormone (LHRH) peptide derivatives that target the LHRH receptor; LHRH peptide-drug conjugates (LHRH-PDCs); and methods of using the derivatives and / or conjugates thereof to treat an LHRH receptor expressing cancer.SOLUTION: The present invention provides a LHRH peptide-drug conjugate (LHRH-PDC) or a pharmaceutically acceptable salt thereof, comprising the following sequence: X1-His-Trp-Ser-X2-X3(L-D)-X4-X5-Pro-NHR, where X1 is pGlu; X2 is Tyr, Phe, or His; X3 is D-Lys(Ahx); X4 is Leu, Val, Trp, or Met; X5 is Arg, Gln, Trp, Ser, Leu, Asn, Phe, Tyr, or Lys; R is CH2CH3 or CH3; L is a linker; and D is a cytotoxic agent.SELECTED DRAWING: None

The invention discloses preparation and new application of growth hormone releasing hormone similar peptide monomers, dimers and tetramers, which can regulate the synergistic expression of human organ autocrine GHRH receptor down and GHSR up and down, directly promote the proliferation and / or activation of organ mesenchymal stem cells, and can be used for preparing medicines for treating organ injury, protecting diseases, and preventing and treating diseases. The compounds can be used as anti-aging, organ injury protection, cancer chemotherapy protection, anti-cancer drugs and the like.

The invention discloses application of cycloastragenol in preparation of a product for treating male sexual dysfunction, and relates to the technical field of biological medicine, sexual dysfunction of male mice caused by high-fat diet, medicine and aging is remarkably improved through intervention of cycloastragenol, the specific expression is that changes of body weight and testis weight are controlled, and the sexual dysfunction of the male mice caused by high-fat diet, medicine and aging is improved. The sperm motility rate is obviously improved, the hormone release level of testosterone and gonadotropin is increased, and the testicular tissue structure is improved.

The invention discloses a probiotic medicinal and edible medicinal material composition as well as a preparation method and application thereof. The composition comprises combined probiotics and medicinal and edible medicinal materials, the combined probiotics comprise Lactobacillus plantarum JY001 and Lactobacillus plantarum JY002, and the medicinal and edible medicinal materials comprise cistanche deserticola, semen raphani, peach kernels, astragalus membranaceus, codonopsis pilosula and pericarpium citri reticulatae. The composition takes medicinal and edible medicinal materials as raw materials, has the effect of improving endocrine hormone disorder caused by chronic stress after being fermented by combined probiotics, and can be applied to preparation of products for improving endocrine hormone disorder caused by chronic stress; the composition is especially applied to preparation of products for reversing reduction of thyroid stimulating hormone release hormone, adrenocorticotropic hormone and / or testosterone secretion level caused by chronic stress, and meanwhile, the composition also meets the requirements of people for resisting fatigue and improving constipation due to intestinal dryness.

The present invention relates to cancer vaccines and methods of treatment using the same. Disclosed is a vaccine composition, the present invention relates to a composition comprising one or more nucleic acids encoding one or more amino acid sequences selected from the group consisting of a tyrosinase, a tyrosinase-associated protein 1, a tyrosinase-associated protein 2, a melanoma-associated antigen 4 protein, a growth hormone releasing hormone, a MART-1 / melan-A antigen, a cancerous testis antigen NY-ESO-1, a cancerous testis antigen NY-ESO-2, the amino acid sequences of the antigen, the Vilms tumor 1 and the human telomerase reverse transcriptase are preferentially expressed in the melanoma. The vaccine compositions may further comprise nucleic acids encoding one or more other antigens, including prostate-specific antigens. Also disclosed are methods of preventing or treating cancer in a subject in need thereof, comprising administering to the subject a vaccine composition comprising a specific amount of cancer antigens to treat or prevent a specific cancer.

The invention discloses application of polydatin in preparation of a medicine for improving and repairing cryptorchis spermatogenic function damage, and belongs to the technical field of biological medicine. The medicine takes polydatin as a main active ingredient. Experiments prove that the polydatin can effectively improve the spermatogenic function, promote the reproductive repair of a mouse with cryptorchis and improve the hormone release level of serum testosterone and gonadotropin, the hormone is beneficial to spermatogenesis, the repair effect has a dose effect, and the repair effect is optimal when the polydatin concentration is 50-100mg / kg. In addition, metabolome in the testis of the mouse can be adjusted, oxidative stress and inflammatory response are relieved, and therefore sperm counting and epididymis weight are affected and improved. According to the scheme, an experimental basis is provided for application of polydatin in the field of reproductive health, and a new candidate medicine is also provided for treatment of male infertility such as hidden testis.

The present invention belongs to the field of biomedicine and mainly relates to the use of the growth hormone-releasing hormone receptor agonist MR-409 in the preparation of non-alcoholic fatty liver disease (NAFLD) drugs. Currently, there are no targeted drugs for the treatment of NAFLD, and lipid-lowering drugs are usually used in combination with liver-protecting drugs. MR-409 is a new type of GHRHR-A. GHRHR is widely expressed in the liver and pancreas, and literature reports that GHRHR-A has the effects of improving islet function, promoting the survival of transplanted islets, and alleviating diabetic eye complications. In the present invention, the study found that MR409 can improve the imaging, serum enzymology, serum metabolism, and histological indicators of non-alcoholic fatty liver disease in diabetic mice, and is expected to become a therapeutic drug for non-alcoholic fatty liver disease. The present invention provides a new use of MR-409 for the treatment of non-alcoholic fatty liver disease, provides a new strategy for the treatment of non-alcoholic fatty liver disease, has important clinical therapeutic significance, and provides a scientific basis for its future development into a drug for the treatment of non-alcoholic fatty liver disease.

The invention relates to the technical field of treatment of diabetic nephropathy, in particular to application of a growth hormone releasing hormone GHRH agonist in preparation of a medicine for preventing and treating kidney diseases. The invention provides an application of a growth hormone releasing hormone GHRH agonist in preparation of a medicine for preventing and / or treating kidney diseases, verifies that the growth hormone releasing hormone GHRH agonist GHRH-6A can relieve diabetic nephropathy by relieving oxidative stress and inhibiting ferroptosis for the first time, and has important significance in prevention and treatment of diabetic nephropathy. And a new thought is provided for prevention and treatment of diabetic nephropathy.